research use only

6-Diazo-5-oxo-L-norleucine (Diazooxonorleucine) Glutaminase antagonist

Name: 6-Diazo-5-oxo-L-norleucine (Diazooxonorleucine)
Brand: Selleck Chemicals
SKU: S8620
Availability: InStock
Rating: 5 (9 reviews)

Cat.No.S8620

6-Diazo-5-oxo-L-norleucine (Diazooxonorleucine, L-6-Diazo-5-oxonorleucine, DON), an antibiotic isolated from Streptomyces, is a glutaminase antagonist with IC50 of ~1 mM for cKGA (kidney-type glutaminase). 6-Diazo-5-oxo-L-norleucine exhibits analgesic, antibacterial, antiviral and anticancer properties.

Chemical Structure

Molecular Weight: 171.15

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: Purity: 99.91%

99.91

Related Targets	HDAC Caspase MMP HCV Protease Cysteine Protease DPP Tyrosinase HIV Protease Proteasome Serine Protease Secretase PCSK9 Acyltransferase Thrombin Cathepsin B MALT PAD PREP Neprilysin Carboxypeptidase SGK Aminopeptidase 3C-Like Protease PSMA PGDS GOT
Related Products	Telaglenastat (CB-839) BPTES JHU-083 GK921 Zampilimab (Anti-TGM2 / Transglutaminase 2) TGM2 Antibody [K23K16] LDN-27219 JHU395 UPGL00004 IACS-6274 Glutaminase Antibody [D8D1] Glutaminase C-IN-1 Sirpiglenastat (DRP-104) L-Albizziin

Chemical Information, Storage & Stability

Molecular Weight	171.15	Formula	C₆H₉N₃O₃	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	157-03-9	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent

Solubility

In vitro
Batch:

Water : 34 mg/mL

DMSO : Insoluble
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.300mg/ml (1.75mM)	Taking the 1 mL working solution as an example, add 50 μL of 6 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.150mg/ml (0.88mM)	Taking the 1 mL working solution as an example, add 50 μL of 3 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	cKGA ^[1] (Cell-free assay) 1 mM
In vitro	6-Diazo-5-oxo-L-norleucine appears to be positive in the in vitro chromosome aberration assay that it demonstrates dose dependent statistically positive increase in structural aberrations at 4 and 20 hour exposure without S9 and also at 4 hour exposure with S9.^[2]
In vivo	6-Diazo-5-oxo-L-norleucine is evaluated for its in vivo clastogenic activity by detecting micronuclei in polychromatic erythrocyte (PCE) cells in bone marrow collected from the male mice dosed intravenously with 500, 100, 10, 1 and 0.1 mg/kg at 24 and 48 hour post dose. The in vivo micronucleus assay reveals a statistically positive response for micronucleus formation at 500, 100 and 10 mg/kg at 24 and 48 hour post dose.^[2]
References	[1] https://pubmed.ncbi.nlm.nih.gov/24451979/ [2] https://pubmed.ncbi.nlm.nih.gov/28552037/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06373094	Not yet recruiting	Alzheimer Disease	Shanghai Synergy Pharmaceutical Sciences Co. Ltd.\|Zhejiang Huahai Pharmaceutical Co. Ltd.	June 1 2024	Phase 1
NCT06261541	Recruiting	Multiple Sclerosis	ABLE Human Motion S.L.\|Fundación Esclerosis Múltiple Madrid (FEMM)	April 8 2024	Not Applicable
NCT06167954	Recruiting	Cerebral Palsy\|Acquired Brain Injury\|Spinal Muscular Atrophy	MarsiBionics\|Hospital Infantil Universitario Niño Jesús Madrid Spain\|Hospital Universitario La Paz\|Hospital Universitario 12 de Octubre\|Hospital General Universitario Gregorio Marañon	December 4 2023	Not Applicable
NCT05914818	Completed	Cerebral Palsy\|Acquired Brain Injury\|Neuromuscular Diseases in Children	MarsiBionics\|National Research Council Spain\|Hospital Infantil Universitario Niño Jesús Madrid Spain\|Hospital Universitario La Paz\|Hospital Universitario 12 de Octubre\|Hospital General Universitario Gregorio Marañon	June 23 2023	Not Applicable

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):